Incannex updates on IHL-42X dosing, new patent, and $70 million cash position
Incannex Healthcare confirmed dosing has begun in its DReAMzz sleep apnea trial and disclosed a new U.S. patent and roughly $70 million in cash with no debt.
SEC filing
Latest
3 stories
Wednesday, September 9
Tuesday, August 25
Incannex doses first patient in Phase 2 DReAMzz trial of IHL-42X
The dose-optimization study for the obstructive sleep apnea drug candidate follows earlier Phase 2 results and FDA Fast Track designation.
SEC filing
Thursday, July 23
Incannex begins screening patients in Phase 2 sleep apnea trial of IHL-42X
The company said its first approved clinical sites are now screening participants for the DReAMzz study ahead of planned Phase III development.
SEC filing